Jose Antonio Lorente, M.D., Ph.D.
Oncological Genomic Area
Principal Investigator & Head of Liquid Biopsy and Cancer Interception Group
Full contact details
Prof. Jose A. Lorente, M.D., Ph.D.
Scientific Director – GENYO
GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government
Av. Ilustración, 114 – PTS
18016 – Granada, Spain
Tel. +34 958 715 500 – Fax +34 958 637 071 – https://www.genyo.es
School of Medicine – PTS – Tower C – 9th floor – University of Granada
18016 – Granada, Spain
Tel.: +34 958 243 546 – Fax: +34 958 246 107 – www.ugr.es
1985 University of Granada MD degree – Medicine & Surgery
1989 University of Granada PhD degree – Medicine & Surgery
1987 Ministry of Education Specialist in Occupational Medicine
1990 Ministry of Education Specialist in Forensic & Legal Medicine
1989-1990 – University of Heidelberg (Germany) & University of Münster (Germany)
1992-1993 – FBI Academy & University of California Berkeley (USA)
1994- University of Granada – Associate Professor
2007- GENyO – Scientific Director
2012 University of Granada – Full professor
In 1985 I graduated in Medicine & Surgery at the School of Medicine and Surgery of the University of Granada. I became Specialist in Occupational Medicine (1987), and also Specialist in Legal Medicine (1990), and became Ph.D. in Medicine with honours (Extraordinary Prize) in 1989, all at the University of Granada.
Once I got my Ph.D. I moved to the Universities of Heidelberg (1989) and Münster (1989-1990), in Germany, to learn about DNA analysis and its applications to human identification.
In 1991 I created the laboratory of genetic at the University of Granada, and then moved to the USA 1992-1993 to work at the FBI Academy and at the University of California Berkeley (UCB) on the new technologies of short tandem repeats and automated DNA sequencing.
Once back in Spain, in Granada, I started to focus in the forensic analysis of degraded samples and minimum amounts of DNA (traces).
I have been always interested in human-rights related problems and in the use of genetics not only to solve, but also to prevent crimes, and I created as a pioneer 3 worldwide programs to identify missing persons (Phoenix program, 1998), to fight children trafficking (DNA-PROKIDS, 2004) and to fight organ trafficking (DNA-PRO-ORGAN, 2016).
Along that time, and since 1998, I started to have contacts with clinical colleagues interested in getting DNA results (sequences, STRs) from clinical specimen of reduced size and limited number of cells (i.e., biopsies, microscope slides).
In the year 2000 I split my DNA team in 2, one for forensics, the other one for medical genomics, and we started to work with challenging clinical samples coming from blood of patients.
In 2006 I envisioned and promoted the creation of GENYO, nowdays known as Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, and I was appointed its Scientific Director in 2007.
We started to work along with Dr. Maria Jose Serrano focused on circulating tumor cells (CTCs) and later on, with the recent development of the concept of liquid biopsy, we are also working with cell-free circulating DNA, tumor-free DNA, exosomes and micro-RNAs.
Our main interest is in the area of cancer, but not limited to that. In the oncology filed we’re interested in cancer interception, the ability to detect cancer in its earliest phases, allowing hence the possibility of more successful treatments.
My work continues at the University of Granada and at GENYO, a centre for medical genomics and oncological research that I envisioned in 2006, and that was inaugurated in 2010; I have been the Scientific Director since it was first approved and legally created (2007), and where I have my Liquid Biopsy & Cancer Interception Group.
1 Scientific paper. Diego de Miguel-Perez; et al; MJ Serrano. 2019. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients Scientific Reports. ISSN 2045-2322.
2 Scientific paper. Diego de Miguel -Perez; et al; MJ Serrano. 2019. Post-surgery circulating tumor cells and AXL overexpression as new poor prognostic biomarkers in resected lung adenocarcinoma Cancers. MDPI. 11-11, pp.1750. ISSN 2072-6694.
3 Scientific paper. Serrano MJ. 2019. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents.Cells. MID. 8-11, pp.1382-1385. ISSN 2073-4409.
4 Scientific paper. Ortega FG; Serrano MJ; Fernandez baldo MA. 2019. EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform Talanta. Elservier. 194, pp.243-252. ISSN 0039-9140.
5 Scientific paper. Rodríguez-Martínez A; de Miguel-Pérez D; Serrano MJ. 2019. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast cancer research. Springer Nature. 21-1, pp.21-26. ISSN 1465-542X.
6 Scientific paper. Malapelle U; et al. 2019. Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.Journal Thoracic Disease. pISSN: 2072-1439; eISSN: 2077-6624. 10-12, pp.6388-6391. ISSN 2077-6624.
7 Scientific paper. Pedro J Romero; Serrano MJ. 2019. Liquid biopsy beyond cancer: Circulating Pulmonary Cells as biomarkers of COPD aggressivity Critical Review in Oncology and Hematology. 136, pp.31-36. ISSN 1040-8428.
8 Scientific paper. Delgado-Ureña M; Serrano. 2018. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.J Transl Med.16-1, pp.251-256. ISSN 1479-5876.
9 Scientific paper. Puche-Sanz I; et al. 2017. A comprehensive study of circulating tumour cells at the moment of prostate cancer diagnosis: Biological and clinical implications of EGFR, AR and SNPs.Oncotarget. 1949-2553. ISSN 1949-2553.
10 Scientific paper. Bayarri-Lara CI; et al. 2017. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers†.Eur J Cardiothorac Surg. oxford academy. ISSN 1010-7940.
11 Scientific paper. C Bayarri; et al. 2016. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection Plos One. 11-2. ISSN 1932-6203.
12 Scientific paper. J Torres; et al. 2016. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC).Surgery. 159-3, pp.728-35. ISSN 0039-6060.
13 Scientific paper. FG Ortega; et al. 2015. Study of antitumor activity in breast cell lines using silver nanoparticles produced by yeast.Int J Nanomedicine. 16-10, pp.2021-2031.
14 Scientific paper. Ortega FG; et al. 2015. miRNA in situ hybridization in circulating tumor cells–MishCTC Sci Rep.17-5, pp.9207. ISSN 2045-2322.
15 Scientific paper. MJ Serrano; et al. 2014. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.Oncotarget. 15-5, pp.7486-7497. ISSN 1949-2553.
16 Scientific paper. R Nadal; et al. 2013. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.Int J Cancer. 133-10, pp.2398-2407. ISSN 1097-0215.
17 Scientific paper. A Fernández; et al. 2012. Biomarkers characterization of circulating tumour cells in breast cancer patients.Breast Cancer Re. 14-3, pp.R71. ISSN 1465-542X.
18 Scientific paper. R Rosell; MA Molina; MJ Serrano. 2012. EGFR mutations in circulating tumour DNA.Lancet Oncol.3-10, pp.971-973. ISSN 1470-2045.
19 Scientific paper. MJ Serrano; et al. 2011. Circulating cancer cells in division in an early breast cancer patient.Ann Oncol.22-9, pp.21-25. ISSN 0923-7534.
20 Review. Rolfo C; et al; Serrano MJ. 2020. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) Journal of Clinical Oncology. ASCO. APRIL. ISSN 1527-7755. 20 6;21(1):21. doi: 10.1186/s13058-019-1109-0.
21 Gómez-Martín A, Martinez-Gonzalez LJ, Puche-Sanz I, Cozar JM3, Lorente JA, Hernández AF, Alvarez-Cubero MJ. GSTM1 gene expression and copy number variation in prostate cancer patients-Effect of chemical exposures and physical activity. Urol Oncol. 2019 Apr;37(4):290.e9-290.e15. doi: 10.1016/j.urolonc.2018.12.010.
22 Cruz-Lozano M, González-González A, Marchal JA, Muñoz-Muela E, Molina MP, Cara FE, Brown AM, García-Rivas G, Hernández-Brenes C, Lorente JA, Sanchez-Rovira P, Chang JC, Granados-Principal S. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways. Eur J Nutr.2019 Dec;58(8):3207-3219. doi: 10.1007/s00394-018-1864-1.
23 Alvarez-Cubero MJ, Santiago O, Martínez-Labarga C, Martínez-García B, Marrero-Díaz R, Rubio-Roldan A, Pérez-Gutiérrez AM, Carmona-Saez P, Lorente JA, Martinez-Gonzalez LJ. Methodology for Y Chromosome Capture: A complete genome sequence of Y chromosome using flow cytometry, laser microdissection and magnetic streptavidin-beads. Sci Rep. 2018 Jun 21;8(1):9436. doi: 10.1038/s41598-018-27819-x.